ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1812

The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus

Tomonori Ishii1, Yoshiya Tanaka2, Atsushi Kawakami3, Kazuyoshi Saito2, Kunihiro Ichinose4, Yuko Shirota5, Hiroshi Fujii5, Yoko Fujita6, Yukiko Kamogawa5, Tomoaki Machiyama5, Kanae Akita5 and Hideo Harigae5, 1Department of Clinical Trial Implementation, Tohoku University Hospital, Clinical Research, Innovation and Education Center, Sendai, Japan, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 6Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: B cell targeting, Bortezomib, RCT, SLE and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell line have been reported as new approaches to SLE treatment. Bortezomib is a proteasome inhibitor targeting plasma cells, and is widely used in the treatment of plasma cell tumors. Here, we evaluated the efficacy and safety of bortezomib versus placebo for the treatment of SLE cases in which disease activity could not be controlled by conventional combined use of immunosuppresssants and steroids.

Methods:

Fourteen patients in whom the dose of predonine could not be reduced to ≤10 mg/day despite the concomitant immunosuppressive therapy and moderate disease activity persisted (SLEDAI, ≥6 points; positive for anti-dsDNA antibody) were randomized by using the anti-dsDNA antibody as a randomization factor. Bortezomib, 1.3 mg/m2, or placebo was administered twice weekly, 8 times in total to patients. Endpoints were changes in anti-dsDNA antibody titer at Week 24 and SLE responder index (SRI).

Results:

Among the 14 patients, 8 and 6 patients were assigned to the bortezomib group and the placebo group, respectively; however, 4 of the 8 patients in the bortezomib group and 2 of the 6 patients in the placebo group discontinued the trial. The reason for discontinuation was inability to continue the trial due to adverse reactions in all of the 4 patients in the bortezomib group, and insufficient effects in both of the 2 patients in the placebo group. In the bortezomib group, only one patient could complete the treatment as planned, while 7 others failed to complete the minimum protocol treatment because of adverse reactions. Four patients each in the bortezomib and placebo groups, who could complete the trial, were included in the following analysis.

The percent change of the anti-dsDNA antibody titer at treatment 24, which was defined as the primary endpoint, was 4.24% in the bortezomib group and -1.96% in the placebo group, which did not support the efficacy of bortezomib. However, when LOCF analysis was used by including the patients who discontinued the treatment, -11.34% and 23.88% were obtained as reference values in the bortezomib and placebo groups, respectively, suggesting that the patients who needed to discontinue the trial because of adverse reactions might have responded well to bortezomib. On the other hand, the SRI at Week 12 was 75% in the bortezomib group and 40% in the placebo group. Although the difference did not reach statistical significance, these results appear to be promising in terms of the efficacy of bortezomib.

Conclusion:

Since bortezomib therapy for SLE is associated with many adverse reactions, it is necessary to select indications carefully and to establish the protocol aiming at the prevention of adverse reactions. On the other hand, we observed improvement of clinical findings such as skin symptoms, regardless of the anti-dsDNA antibody titer, in a patient in the bortezomib group. In fact, SRI tended to be high in the bortezomib group. These findings suggest that bortezomib may be effective in treating various symptoms of SLE though the mechanism other than inhibition of anti-dsDNA antibody production.


Disclosure: T. Ishii, None; Y. Tanaka, BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbvie, Daiichi-Sankyo, 2,UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei, 5; A. Kawakami, None; K. Saito, None; K. Ichinose, None; Y. Shirota, None; H. Fujii, None; Y. Fujita, None; Y. Kamogawa, None; T. Machiyama, None; K. Akita, None; H. Harigae, None.

To cite this abstract in AMA style:

Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Shirota Y, Fujii H, Fujita Y, Kamogawa Y, Machiyama T, Akita K, Harigae H. The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-first-randomized-control-trial-to-evaluate-the-effectiveness-of-bortezomib-for-refractory-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-first-randomized-control-trial-to-evaluate-the-effectiveness-of-bortezomib-for-refractory-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology